mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.084 |
0.01 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.084 |
0.01 |
mRNA |
Docetaxel |
gCSI |
pan-cancer |
AAC |
-0.13 |
0.01 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.02 |
mRNA |
BRD-A05715709 |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.02 |
mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.02 |
mRNA |
NVP-ADW742 |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.02 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.074 |
0.02 |
mRNA |
ciclosporin |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.02 |